Article
Source: Campus Sanofi
May 15, 2025

Unmet needs in adults with T2D receiving premixed insulin

Author: Sanofi

Editorial Team

Suboptimal glycemic target achievement is common in people with T2D

In a meta-analysis of 24 studies across 20 countries: the proportion of people achieving HbA1c targets was 43%.¹
According to the IDMPS: <50% of participants achieved a glycaemic goal of HbA1c <7% in LMICs²

Real-world evidence shows poor glycemic control with premix

<20%: UK THIN: <20% achieved HbA1c <7.5% 24 months after initiating with premix insulin³
∼20%: IDMPS: ~20% on premix insulin reached HbA1c <7% in LMICs⁴
>28%: CoDiC: >28% had their HbA1c >8% for 17 months after switching from BI to premix insulin⁵

Many people with T2D eventually require injectable therapy.^6-8

Globally, 30% of people with T2D use premix insulin9, but this is associated with:

Greater bodyweight gain vs BI:¹⁰

Premix insulin: +0.8 kg to +5.4 kg
BI: +0.1 kg to +3.5 kg

Increased hypoglycemia risk vs BI¹⁰

Premix insulin: 3.4 to 8.2 events PPY
BI: 0.7 to 5.4 events PPY

Abbreviations

Reference

MAT-BH-2300653/v1/October 2023

Suboptimal glycemic target achievement is common in people with T2D

Real-world evidence shows poor glycemic control with premix

Many people with T2D eventually require injectable therapy.6-8

Greater bodyweight gain vs BI:10

Increased hypoglycemia risk vs BI10

Related

Many people with T2D eventually require injectable therapy.^6-8

Greater bodyweight gain vs BI:¹⁰

Increased hypoglycemia risk vs BI¹⁰